ERBB2 and neoplasm: In another study, comprehensive circulating tumor deoxyribonucleic acid (ctDNA) NGS successfully detected ERBB2 amplification in 96.6% (28/29) of the intent-to-treat group; this indicates that ctDNA can serve as a substitute for tissue [64].